A panel of investigational monoclonal antibodies (mAbs) concentrating on completely different websites of the Epstein-Barr virus (EBV) blocked an infection when examined in human cells in a laboratory setting. Furthermore, one of many experimental mAbs offered almost full safety towards EBV an infection and lymphoma when examined in mice.